Clinical Trials Logo

In-Stent Restenosis clinical trials

View clinical trials related to In-Stent Restenosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05731700 Active, not recruiting - In-stent Restenosis Clinical Trials

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

NCT ID: NCT04647253 Active, not recruiting - In-Stent Restenosis Clinical Trials

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

AGENT IDE
Start date: May 11, 2021
Phase: Phase 3
Study type: Interventional

AGENT IDE is a Prospective, Randomized (2:1), Multicenter Trial. The purpose of this study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter compared to balloon angioplasty (POBA) in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 26 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.

NCT ID: NCT04079192 Active, not recruiting - Clinical trials for Coronary Artery Disease

Biolimus A9™ (BA9™) Drug Coated Balloon (DCB) Study

REFORM
Start date: August 7, 2020
Phase: N/A
Study type: Interventional

The study is a Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the BA9™ Drug Coated Balloon for the Treatment of In-Stent Restenosis. It is a First-in-Man Trial.

NCT ID: NCT03529006 Active, not recruiting - In-stent Restenosis Clinical Trials

Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis

Start date: March 2015
Phase: N/A
Study type: Interventional

The primary objective of this study is to demonstrate superiority of the Absorb scaffold compared to the Sequent Please Drug Coated Balloon when treating patients with In-Stent-Restenosis (ISR).

NCT ID: NCT01239953 Active, not recruiting - In-Stent Restenosis Clinical Trials

RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)

RIBS V
Start date: January 2010
Phase: Phase 4
Study type: Interventional

Treatment of patients with bare metal stent restenosis remains a challenge. This study will assess which interventional strategy (paclitaxel-eluting balloon vs everolimus-eluting stent) is superior in the treatment of patients suffering from bare metal stent restenosis.

NCT ID: NCT01127958 Active, not recruiting - In-stent Restenosis Clinical Trials

DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.

Start date: May 2010
Phase: N/A
Study type: Interventional

The main objective of the study is to determine whether PCI for in-stent restenosis with a drug eluting balloon is angiographically non-inferior to PCI with a drug eluting stent at 6 month follow up.

NCT ID: NCT00998439 Active, not recruiting - In-Stent Restenosis Clinical Trials

Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The aim of the study is to assess the efficacy of the Paclitaxel-eluting PTCA - balloon catheter SeQuent® Please to treat in-stent restenoses (ISR) of various drug eluting stents in native coronary arteries with reference diameters between 2.5 mm and ≤ 3.5 mm and lesion lengths ≤ 22 mm. The vessel patency following treatment with SeQuent® Please will be documented in ISR patients that have been treated with the Cypher® or Taxus® drug eluting stent.